Brian Gorman - Calliditas Therapeutics Group Counsel
| CALT Stock | USD 21.50 0.50 2.27% |
Executive
Brian Gorman is Group Counsel of Calliditas Therapeutics
| Age | 48 |
| Address | Kungsbron 1, D5, Stockholm, Sweden, 111 22 |
| Phone | 46 84 11 30 05 |
| Web | https://www.calliditas.se |
Calliditas Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.1281) % which means that it has lost $0.1281 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.8468) %, meaning that it created substantial loss on money invested by shareholders. Calliditas Therapeutics' management efficiency ratios could be used to measure how well Calliditas Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.34 in 2024. Return On Capital Employed is likely to drop to -0.27 in 2024. At this time, Calliditas Therapeutics' Total Current Liabilities is comparatively stable compared to the past year. Non Current Liabilities Total is likely to gain to about 1.2 B in 2024, whereas Liabilities And Stockholders Equity is likely to drop slightly above 1 B in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Michael Halpin | Vericel Corp Ord | 63 | |
| Kathleen Farren | Merus BV | N/A | |
| George Fromm | Shattuck LabsInc | N/A | |
| Douglas CPA | Century Therapeutics | N/A | |
| Jolie JD | C4 TherapeuticsInc | 47 | |
| Laurent MBA | Prelude TherapeuticsInc | 59 | |
| Philip JD | Monte Rosa Therapeutics | 45 | |
| Robin Wagner | Keros TherapeuticsInc | N/A | |
| Anne DVM | Molecular Partners AG | N/A | |
| Mr MBA | C4 TherapeuticsInc | 46 | |
| John MBA | Keros TherapeuticsInc | N/A | |
| Bryant JD | Prelude TherapeuticsInc | 53 | |
| Andrew Combs | Prelude TherapeuticsInc | 58 | |
| Aimee Crombie | Prelude TherapeuticsInc | N/A | |
| Nick MD | Century Therapeutics | N/A | |
| Kendra Adams | C4 TherapeuticsInc | N/A | |
| Robert Hendriks | Molecular Partners AG | N/A | |
| Mike Gilligan | Vericel Corp Ord | N/A | |
| Eric Burns | Vericel Corp Ord | N/A | |
| Patrick Fowler | Vericel Corp Ord | N/A | |
| Ashley PharmD | Merus BV | N/A | |
Management Performance
| Return On Equity | -0.85 | ||||
| Return On Asset | -0.13 |
Calliditas Therapeutics Leadership Team
Elected by the shareholders, the Calliditas Therapeutics' board of directors comprises two types of representatives: Calliditas Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Calliditas. The board's role is to monitor Calliditas Therapeutics' management team and ensure that shareholders' interests are well served. Calliditas Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Calliditas Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| David Ferraro, Head Sales | ||
| AnnKristin BSc, Head Management | ||
| Monika Tornsen, President America | ||
| Renee AguiarLucander, Chief Officer | ||
| Krassimir Mitchev, Head Affairs | ||
| Fredrik Johansson, Chief Officer | ||
| Sandra Frithiof, Head Resources | ||
| Richard MD, Chief Officer | ||
| Katayoun WelinBerger, VP Operations | ||
| Mikael Widell, Head IR | ||
| Jonathan Schur, Group Counsel | ||
| Teona Johnson, Head Marketing | ||
| Brian Gorman, Group Counsel | ||
| Johan Haggblad, Chief Officer |
Calliditas Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Calliditas Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.85 | ||||
| Return On Asset | -0.13 | ||||
| Profit Margin | (0.39) % | ||||
| Operating Margin | 0.05 % | ||||
| Current Valuation | 1.19 B | ||||
| Shares Outstanding | 26.84 M | ||||
| Shares Owned By Institutions | 2.95 % | ||||
| Number Of Shares Shorted | 8.65 K | ||||
| Price To Book | 16.34 X | ||||
| Price To Sales | 0.45 X |
Pair Trading with Calliditas Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Calliditas Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Calliditas Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Calliditas Stock
| 0.63 | ITCI | Intracellular Th | PairCorr |
The ability to find closely correlated positions to Calliditas Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Calliditas Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Calliditas Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Calliditas Therapeutics to buy it.
The correlation of Calliditas Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Calliditas Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Calliditas Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Calliditas Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Calliditas Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. For more information on how to buy Calliditas Stock please use our How to Invest in Calliditas Therapeutics guide.You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Complementary Tools for Calliditas Stock analysis
When running Calliditas Therapeutics' price analysis, check to measure Calliditas Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Calliditas Therapeutics is operating at the current time. Most of Calliditas Therapeutics' value examination focuses on studying past and present price action to predict the probability of Calliditas Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Calliditas Therapeutics' price. Additionally, you may evaluate how the addition of Calliditas Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges |
Is Calliditas Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Calliditas Therapeutics. If investors know Calliditas will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Calliditas Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.62) | Revenue Per Share 44.972 | Quarterly Revenue Growth 0.052 | Return On Assets (0.13) | Return On Equity (0.85) |
The market value of Calliditas Therapeutics is measured differently than its book value, which is the value of Calliditas that is recorded on the company's balance sheet. Investors also form their own opinion of Calliditas Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Calliditas Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Calliditas Therapeutics' market value can be influenced by many factors that don't directly affect Calliditas Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Calliditas Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Calliditas Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Calliditas Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.